First-Line Dacomitinib versus Gefitinib in Advanced Non-Small-Cell Lung Cancer with EGFR Mutation Subgroups

被引：0

作者：

Wu, Y. ^{[1
,2
]}

Cheng, Y. ^{[3
]}

Zhou, X. ^{[4
]}

Lee, K. H. ^{[5
]}

Nakagawa, K. ^{[6
]}

Niho, S. ^{[7
]}

Tsuji, F. ^{[8
]}

Rosell, R. ^{[9
]}

Corral, J. ^{[10
]}

Migliorino, M. R. ^{[11
]}

Pluzanski, A. ^{[12
]}

Linke, R. ^{[13
]}

Sbar, E. ^{[14
]}

Wang, T. ^{[15
]}

Zhang, H. ^{[16
]}

Mok, T. ^{[17
]}

机构：

[1] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China

[2] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

[3] Jilin Prov Canc Hosp, Changchun, Jilin, Peoples R China

[4] Third Mil Med Univ, Affiliated Hosp 1, Chongqing, Peoples R China

[5] Chungbuk Natl Univ Hosp, Chungcheongbuk Do, South Korea

[6] Kindai Univ Hosp, Osaka, Japan

[7] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[8] Sfj Pharma Japan KK, Osaka, Japan

[9] Germans Trias I Pujol Hlth Sci Inst, Catalan Inst Oncol, Barcelona, Spain

[10] Hosp Univ Virgen Del Rocio, Seville, Spain

[11] San Camillo Forlanini Hosp, Pulm Oncol Unit, Rome, Italy

[12] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland

[13] Sfj Pharmaceut Grp, Pleasanton, CA USA

[14] Pfizer Oncol, Collegeville, PA USA

[15] Pfizer Oncol, Groton, CT USA

[16] Pfizer Oncol, Shanghai, Peoples R China

[17] Chinese Univ Hong Kong, Hong Kong, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期

关键词：

EGFR mutations; Dacomitinib; advanced non-small-cell lung cancer;

D O I：

10.1016/j.jtho.2017.09.347

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OA 05.01

引用

页码：S1754 / S1754

页数：1

共 50 条

[41] Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma [J].

Cadranel, Jacques ;

Ruppert, Anne-Marie ;

Beau-Faller, Michele ;

Wislez, Marie .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2013, 88 (03) :477-493

[42] Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations [J].

Jerry Li ;

Dana Nickens ;

Keith Wilner ;

Weiwei Tan .

Oncology and Therapy, 2021, 9 :525-539

[43] FIRST-LINE ERLOTINIB VERSUS CISPLATIN/GEMCITABINE (GP) IN PATIENTS WITH ADVANCED EGFR MUTATION-POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC): INTERIM ANALYSES FROM THE PHASE 3, OPEN-LABEL, ENSURE STUDY [J].

Wu, Yi-Long ;

Liam, Chong-Kin ;

Zhou, Caicun ;

Wu, Gang ;

Liu, Xiaoqing ;

Zhong, Zhaoyang ;

Lu, Shun ;

Cheng, Ying ;

Han, Baohui ;

Chen, Lei ;

Zhu, Yunzhong ;

Qin, Shukui ;

Huang, Cheng ;

Pan, Hongming ;

Liang, Houjie ;

Li, Enxiao ;

How, Soon Hin ;

Jiang, Guoliang ;

Cherry, Marie ;

Fernando, Lynn ;

Chen, Meng ;

Zuo, Yunxia ;

Ladrera, Guia .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S603-S604

[44] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802) [J].

Zhou, C. ;

Wu, Y. L. ;

Chen, G. ;

Feng, J. ;

Liu, X. -Q. ;

Wang, C. ;

Zhang, S. ;

Wang, J. ;

Zhou, S. ;

Ren, S. ;

Lu, S. ;

Zhang, L. ;

Hu, C. ;

Luo, Y. ;

Chen, L. ;

Ye, M. ;

Huang, J. ;

Zhi, X. ;

Zhang, Y. ;

Xiu, Q. ;

Ma, J. ;

Zhang, L. ;

You, C. .

ANNALS OF ONCOLOGY, 2015, 26 (09) :1877-1883

[45] The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study [J].

Cheng, Wen-Chien ;

Lin, Chi-Chien ;

Liao, Wei-Chih ;

Lin, Yu-Chao ;

Chen, Chia-Hung ;

Chen, Hung-Jen ;

Tu, Chih-Yen ;

Hsia, Te-Chun .

BMC CANCER, 2024, 24 (01)

[46] The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study [J].

Wen-Chien Cheng ;

Chi-Chien Lin ;

Wei-Chih Liao ;

Yu-Chao Lin ;

Chia-Hung Chen ;

Hung-Jen Chen ;

Chih-Yen Tu ;

Te-Chun Hsia .

BMC Cancer, 24

[47] Evaluation of the Effect of Proton Pump Inhibitors on the Efficacy of Dacomitinib and Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer and EGFR-Activating Mutations [J].

Li, Jerry ;

Nickens, Dana ;

Wilner, Keith ;

Tan, Weiwei .

ONCOLOGY AND THERAPY, 2021, 9 (02) :525-539

[48] Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations [J].

T. Masuda ;

H. Imai ;

T. Kuwako ;

Y. Miura ;

R. Yoshino ;

K. Kaira ;

K. Shimizu ;

N. Sunaga ;

Y. Tomizawa ;

S. Ishihara ;

A. Mogi ;

T. Hisada ;

K. Minato ;

A. Takise ;

R. Saito ;

M. Yamada .

Clinical and Translational Oncology, 2015, 17 :702-709

[49] A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam [J].

Cam Phuong Pham ;

Thi Thai Hoa Nguyen ;

Anh Tu Do ;

Tuan Khoi Nguyen ;

Thi Anh Thu Hoang ;

Tuan Anh Le ;

Dinh Thy Hao Vuong ;

Dac Nhan Tam Nguyen ;

Van Khiem Dang ;

Thi Oanh Nguyen ;

Van Luan Pham ;

Minh Hai Nguyen ;

Thi Huyen Trang Vo ;

Hung Kien Do ;

Ha Thanh Vu ;

Thi Thuy Hang Nguyen ;

Van Thai Pham ;

Le Huy Trinh ;

Khac Dung Nguyen ;

Hoang Gia Nguyen ;

Cong Minh Truong ;

Tran Minh Chau Pham ;

Thi Bich Phuong Nguyen .

BMC Cancer, 24

[50] A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam [J].

Pham, Cam Phuong ;

Nguyen, Thi Thai Hoa ;

Do, Anh Tu ;

Nguyen, Tuan Khoi ;

Hoang, Thi Anh Thu ;

Le, Tuan Anh ;

Vuong, Dinh Thy Hao ;

Nguyen, Dac Nhan Tam ;

Dang, Van Khiem ;

Nguyen, Thi Oanh ;

Pham, Van Luan ;

Nguyen, Minh Hai ;

Vo, Thi Huyen Trang ;

Do, Hung Kien ;

Vu, Ha Thanh ;

Nguyen, Thi Thuy Hang ;

Pham, Van Thai ;

Trinh, Le Huy ;

Nguyen, Khac Dung ;

Nguyen, Hoang Gia ;

Truong, Cong Minh ;

Pham, Tran Minh Chau ;

Nguyen, Thi Bich Phuong .

BMC CANCER, 2024, 24 (01)

← 1 2 3 4 5 →